What is Macrophage Activation Syndrome (MAS)?
Macrophage activation syndrome (MAS) is a potentially life-threatening hyperinflammatory complication characterized by excessive activation and expansion of T lymphocytes (mainly CD8+) and hemophagocytic macrophages that produce a cytokine storm, most commonly occurring in patients with Still's disease (systemic juvenile idiopathic arthritis and adult-onset Still's disease). 1, 2
Core Pathophysiology
MAS represents a state of immune hyperactivation driven by impaired cytolytic activity in natural killer cells and cytotoxic T lymphocytes. This defect leads to:
- Prolonged survival of target cells with increased proinflammatory cytokine production
- Cytokine storm involving markedly elevated IL-1β, IL-6, IL-18, TNFα, and particularly IFNγ
- Overstimulation of macrophages resulting in hemophagocytosis
- Multisystem end-organ dysfunction that can be fatal 3, 4, 5
The underlying mechanism shares pathophysiology with hemophagocytic lymphohistiocytosis (HLH), though MAS is considered secondary (triggered by underlying disease) rather than primary (genetic) 3.
Clinical Presentation
Key manifestations to recognize immediately:
- Unremitting high fever (≥39°C/102.2°F)
- Cytopenias (anemia, thrombocytopenia, leukopenia)
- Hepatosplenomegaly and liver dysfunction (elevated transaminases)
- Coagulopathy resembling disseminated intravascular coagulation
- Extreme hyperferritinemia (often >10,000 ng/mL)
- Neurological involvement (altered mental status, seizures)
- Generalized rash and lymphadenopathy 4, 6, 5
Laboratory findings include neutrophilic leukocytosis (initially), elevated CRP, increased fibrinogen and D-dimers, and elevated platelet count that may subsequently drop 2.
Disease Associations
While MAS can complicate various autoimmune inflammatory rheumatic diseases, it occurs most frequently in Still's disease (both systemic juvenile idiopathic arthritis and adult-onset Still's disease), particularly in children under age 2. Other associations include:
- Systemic lupus erythematosus
- Kawasaki disease
- Juvenile dermatomyositis
- Rheumatoid arthritis
- Sjögren's syndrome 4, 6
Critical caveat: MAS can occur at disease onset, during treatment, or even when the underlying disease is in remission—especially triggered by infection. This means physicians must maintain constant vigilance even in patients with well-controlled disease 2.
Genetic Predisposition
Recent whole exome sequencing studies demonstrate that patients with Still's disease-associated MAS carry an increased burden of rare protein-altering variants affecting the perforin-mediated cytolytic pathway compared to healthy controls. Even heterozygous variants can partially reduce cytolytic activity, predisposing to MAS—though this differs from the autosomal recessive inheritance pattern of primary HLH 7.
Management Implications
Prompt detection and rapid treatment are essential given the life-threatening nature of MAS. According to the most recent 2024 EULAR/PReS guidelines, high-dose glucocorticoids combined with IL-1 inhibition or IFNγ inhibition represent the best available treatment strategy, despite limited data 1. Cyclosporine remains an option for refractory cases 5.
Patients with severe MAS should be managed in collaboration with Still's disease expert centers 2.